Clinical Management of Wilson's Disease

Wilson’s disease is an autosomal recessive disorder characterised by impaired biliary copper excretion and consequent accumulation of copper in the liver, brain and other organs. Clinical management begins with timely diagnosis through assessment of serum ceruloplasmin, non-ceruloplasmin bound copper and 24-hour urinary copper excretion, supplemented by hepatic imaging or biopsy when required. First-line treatment comprises lifelong copper chelation therapy, typically with D-penicillamine or trientine, aimed at mobilising stored copper and enhancing urinary elimination. In patients with predominantly hepatic presentation, zinc salts can be employed to inhibit intestinal copper absorption, offering a favourable safety profile in mild to moderate disease. Neurological manifestations often demand careful initiation of chelation to avoid paradoxical worsening, and may require adjunctive symptomatic therapies for movement disorders. Regular monitoring of liver function, copper indices and haematological parameters is essential to detect adverse effects and to ensure adherence. In cases of acute liver failure or decompensated cirrhosis, liver transplantation remains the definitive curative option. Emerging approaches include novel chelators with improved binding characteristics, gene therapy strategies to correct ATP7B defects and targeted management of extrahepatic complications. Multidisciplinary care with hepatologists, neurologists and specialist nurses is critical to optimise long-term outcomes and quality of life.

Research from Nature Portfolio

Recent studies have quantitatively characterised the copper-binding affinities of major decoppering drugs, revealing that binding strength varies over several orders of magnitude and correlates with molecular sulphur content and spatial configuration. Structure–activity analyses have highlighted α-lipoic acid as a promising endogenous agent capable of protecting hepatic cells from copper toxicity, suggesting a new avenue for therapeutic development. Complementary proteomic investigations in murine models with systemic versus hepatocyte-specific deletion of Atp7b have delineated distinct metabolic adaptations to copper overload: global inactivation triggers enhanced inflammatory and chromosomal replication responses, while hepatocyte-only deletion dysregulates lipid and nucleic acid metabolism. These findings have identified potential biomarkers such as reduced glucokinase and elevated mucin-13, offering prospects for improved diagnostic precision and personalised treatment strategies.

Clinical Management of Wilson's Disease publication trend

The graph below shows the total number of articles in clinical management of wilson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Wilson’s disease: inherited disorder of copper metabolism caused by pathogenic variants in ATP7B, leading to copper accumulation and organ damage.

ATP7B: gene encoding a P-type copper-transporting ATPase responsible for hepatic copper excretion into bile.

Copper chelation therapy: pharmacological approach using small molecules to bind excess copper and promote its urinary or biliary elimination.

Ceruloplasmin: copper-binding ferroxidase in the bloodstream that serves as a biomarker of copper status and transport capacity.

Bis-choline tetrathiomolybdate (TTM): investigational copper chelator designed to reduce intestinal copper absorption and limit tissue deposition.

References

1. Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease. Journal of Hepatology (2023).
2. Advances in Treatment of Wilson Disease. Tremor and Other Hyperkinetic Movements (2018).
3. Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent. Scientific Reports (2018).
4. Wilson’s Disease: An Update on the Diagnostic Workup and Management. Journal of Clinical Medicine (2021).
5. Systemic deletion of Atp7b modifies the hepatocytes’ response to copper overload in the mouse models of Wilson disease. Scientific Reports (2021).